Medical Condition

advanced solid tumor

Total Trials

32

Recruiting Now

32

Trial Phases

Phase 1, Phase 2, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for advanced solid tumor sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.

Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
Phase 1–4 studies from early safety trials to post-marketing surveillance
NIH, pharmaceutical sponsor, and academic medical center studies worldwide
AI-powered plain-language summary available for every trial listing

Frequently Asked Questions — advanced solid tumor Clinical Trials

How many clinical trials are currently recruiting for advanced solid tumor?

ClinicalMetric currently tracks 32 actively recruiting clinical trials for advanced solid tumor, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 32. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for advanced solid tumor?

advanced solid tumor research spans Phase 1 (29 trials), Phase 2 (14 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a advanced solid tumor clinical trial?

Eligibility criteria for advanced solid tumor trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Top Sponsors

Robert Bok, MD, PhD 1 trial

LaNova Medicines Limited 1 trial

Fox Chase Cancer Center 1 trial

Xiaorong Sun 1 trial

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 1 trial

advanced solid tumor

Frequently Asked Questions — advanced solid tumor Clinical Trials

Recruiting Clinical Trials

Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer

A Clinical Study of [225Ac]Ac-FAPI-XT(XT117) Injection in Patients With Advanced Solid Tumors

A Study of FDA022-BB05 in Advanced/Metastatic Solid Tumors

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

ARC101 in Advanced Solid Tumors

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

XTX301 in Patients With Advanced Solid Tumors

A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer

A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants With Advanced Solid Tumors

A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1)

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

A Study of YL201 in Patients With Advanced Solid Tumors

First in Human Study of T3P-Y058-739 (T3P)

A Study of HS-20089 in Patients With Advanced Solid Tumors

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors

A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients

A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors

Study of CHS-114 in Participants With Advanced Solid Tumors

Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions

A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

TR128 in Patients With Advanced Solid Tumors

Safety and Tolerability Study for T-1301 Capsules to Treat Advanced Solid Tumors

A Clinical Study of SYS6023 in Patients With Advanced Solid Tumors

An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies

Study of GS-5319 in Adults With Solid Tumors

Clinical Trial of PM54 in Advanced Solid Tumors Patients.